
Overview
Genetic testing firm's Q4 revenue grew 9% yr/yr, missing analyst expectations
Adjusted EBITDA loss for Q4 missed analyst expectations
Company reported GAAP loss of $23.4 mln, non-GAAP income of $5.2 mln
Outlook
Fulgent expects 2026 revenue of approximately $350 mln
Company anticipates 2026 non-GAAP loss of approximately ($1.45) per share
Fulgent projects cash and investments of approximately $685 mln by end of 2026
Result Drivers
LABORATORY SERVICES - Growth driven by momentum in laboratory services and investments in AI and digital pathology
THERAPEUTIC DEVELOPMENT - Progress in therapeutic pipeline with FID-007 in Phase 2 and FID-022 in Phase 1
OPERATIONAL EFFICIENCIES - Margin improvements due to streamlined operations and enhanced efficiencies
Company press release: ID:nBw5HmR8na
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $83.34 mln | $85.38 mln (3 Analysts) |
Q4 Adjusted EBITDA | Miss | -$4.50 mln | $169,670 (3 Analysts) |
Q4 Pretax Profit | Miss | -$29.27 mln | $2.16 mln (2 Analysts) |
Q4 Gross Profit |
| $32.58 mln |
|
Q4 Operating Expenses |
| $68.82 mln |
|
Q4 Operating Income |
| -$36.24 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Fulgent Genetics Inc is $35.00, about 41.4% above its February 26 closing price of $24.76
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.